I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Cincinnati Children's Hospital Medical Center

Status: Completed

Conditions: Neuroblastoma; Pheochromocytoma

Study type: Observational

Funder types: Other

Identifiers

NCT00590096

CCHMC# 88-12-2

Details and patient eligibility

About

I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

Full description

Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma.

Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

Enrollment: 1,380 patients

Sex: All

Ages: 2+ weeks old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma

Exclusion criteria

• Pregnancy